Unlike previous publications showing a beneficial impact on response to salvage chemotherapy [44], our results argue that in the setting of R/R AML, mutated NPM1 status does not contribute to improved outcomes, a supposition supported also by a recent analysis by Schlenk and colleagues [5]. Here, NPM1 is linked to acute myeloid leukemia.